ID

21433

Descripción

Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1); ODM derived from: https://clinicaltrials.gov/show/NCT00307229

Link

https://clinicaltrials.gov/show/NCT00307229

Palabras clave

Versiones (1)
  1. 21/4/17 21/4/17 -
Subido en

21 de abril de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Metastatic Breast Cancer NCT00307229

Inglés

Eligibility Metastatic Breast Cancer NCT00307229

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. metastatic or locally recurrent breast cancer,
Descripción

Metastatic or locally recurrent breast cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0278488
UMLS CUI [2,1]
C2986682
UMLS CUI [2,2]
C0678222
2. 18 years of age or older,
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
3. her-2/neu positive (3+ by immunohistochemistry or fish +),
Descripción

her-2/neu status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1512413
4. one of the following
Descripción

Inclusion Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1512693
1. currently receiving hormonal therapy or are candidates for such or,
Descripción

Hormone therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0279025
2. being considered for trastuzumab or,
Descripción

Trastuzumab

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0338204
3. their cancer has progressed on trastuzumab
Descripción

Cancer progression on trastuzumab

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1947901
UMLS CUI [1,2]
C0338204
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. pregnant or lactating women.
Descripción

Gynaecological status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. prior or concurrent malignancies except treated basal cell or squamous carcinoma of the skin or in situ cancer of the cervix or any other cancer treated and presumed cured more than five years prior to study entry.
Descripción

Prior malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2735088
3. currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy. [note: concurrent hormonal therapy (tamoxifen,aromatase inhibitors, or megace) is permitted.].
Descripción

Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0392920
UMLS CUI [2,1]
C0521116
UMLS CUI [2,2]
C0021083
UMLS CUI [3,1]
C0521116
UMLS CUI [3,2]
C0860404
UMLS CUI [4,1]
C0521116
UMLS CUI [4,2]
C1531518
4. treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.
Descripción

Date of trastuzumab treatment

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0338204
5. hemoglobin < 80 g/l or granulocytes < 1.5 x 109 /l or lymphocytes < 1.0 x 109 /l or platelets < 100 x 109 /l.
Descripción

Hemoglobin measurement, granulocyte count, lymphocyte count, platelets

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0518015
UMLS CUI [2]
C0857490
UMLS CUI [3]
C0200635
UMLS CUI [4]
C0005821
6. baseline liver enzymes (ast or alt) greater than 3 times upper limit of normal or greater than 5 times upper limit of normal if liver metastases present and/or bilirubin greater than 50 mmol.
Descripción

Liver enzymes, liver metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1287351
UMLS CUI [2]
C0494165
UMLS CUI [3]
C1278039
7. cd4 cells < 0.5 x 109 /l
Descripción

CD4 cell count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0519835
8. patients with documented brain metastases.
Descripción

Brain metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
9. patients with any acute illness that would interfere with vaccination
Descripción

Acute Illness affecting vaccination

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C4061114
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0042196
10. any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).
Descripción

Immunosuppression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021079
11. eastern cooperative oncology group (ecog) performance status of > 2.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
12. patients with a life expectancy of less than 6 months.
Descripción

Life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
13. geographic inaccessibility which would preclude follow-up. patients registered on the trial must be treated and followed at the jewish general hospital.
Descripción

Residency

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0035182
14. failure to give written informed consent.
Descripción

Informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
15. baseline left ventricular ejection fraction (lvef) < 55% by echocardiography or muga scan.
Descripción

Left ventricular ejection fraction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
Volver a la parte superior de la página

Similar models

Eligibility Metastatic Breast Cancer NCT00307229

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Metastatic or locally recurrent breast cancer
Item
1. metastatic or locally recurrent breast cancer,
boolean
C0278488 (UMLS CUI [1])
C2986682 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
Age
Item
2. 18 years of age or older,
boolean
C0001779 (UMLS CUI [1])
her-2/neu status
Item
3. her-2/neu positive (3+ by immunohistochemistry or fish +),
boolean
C1512413 (UMLS CUI [1])
Inclusion Criteria
Item
4. one of the following
boolean
C1512693 (UMLS CUI [1])
Hormone therapy
Item
1. currently receiving hormonal therapy or are candidates for such or,
boolean
C0279025 (UMLS CUI [1])
Trastuzumab
Item
2. being considered for trastuzumab or,
boolean
C0338204 (UMLS CUI [1])
Cancer progression on trastuzumab
Item
3. their cancer has progressed on trastuzumab
boolean
C1947901 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Gynaecological status
Item
1. pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Prior malignancy
Item
2. prior or concurrent malignancies except treated basal cell or squamous carcinoma of the skin or in situ cancer of the cervix or any other cancer treated and presumed cured more than five years prior to study entry.
boolean
C2735088 (UMLS CUI [1])
Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy
Item
3. currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy. [note: concurrent hormonal therapy (tamoxifen,aromatase inhibitors, or megace) is permitted.].
boolean
C0521116 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0521116 (UMLS CUI [2,1])
C0021083 (UMLS CUI [2,2])
C0521116 (UMLS CUI [3,1])
C0860404 (UMLS CUI [3,2])
C0521116 (UMLS CUI [4,1])
C1531518 (UMLS CUI [4,2])
Date of trastuzumab treatment
Item
4. treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.
boolean
C0011008 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])
Hemoglobin measurement, granulocyte count, lymphocyte count, platelets
Item
5. hemoglobin < 80 g/l or granulocytes < 1.5 x 109 /l or lymphocytes < 1.0 x 109 /l or platelets < 100 x 109 /l.
boolean
C0518015 (UMLS CUI [1])
C0857490 (UMLS CUI [2])
C0200635 (UMLS CUI [3])
C0005821 (UMLS CUI [4])
Liver enzymes, liver metastases
Item
6. baseline liver enzymes (ast or alt) greater than 3 times upper limit of normal or greater than 5 times upper limit of normal if liver metastases present and/or bilirubin greater than 50 mmol.
boolean
C1287351 (UMLS CUI [1])
C0494165 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
CD4 cell count
Item
7. cd4 cells < 0.5 x 109 /l
boolean
C0519835 (UMLS CUI [1])
Brain metastases
Item
8. patients with documented brain metastases.
boolean
C0220650 (UMLS CUI [1])
Acute Illness affecting vaccination
Item
9. patients with any acute illness that would interfere with vaccination
boolean
C4061114 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Immunosuppression
Item
10. any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).
boolean
C0021079 (UMLS CUI [1])
ECOG performance status
Item
11. eastern cooperative oncology group (ecog) performance status of > 2.
boolean
C1520224 (UMLS CUI [1])
Life expectancy
Item
12. patients with a life expectancy of less than 6 months.
boolean
C0023671 (UMLS CUI [1])
Residency
Item
13. geographic inaccessibility which would preclude follow-up. patients registered on the trial must be treated and followed at the jewish general hospital.
boolean
C0035182 (UMLS CUI [1])
Informed consent
Item
14. failure to give written informed consent.
boolean
C0021430 (UMLS CUI [1])
Left ventricular ejection fraction
Item
15. baseline left ventricular ejection fraction (lvef) < 55% by echocardiography or muga scan.
boolean
C0428772 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial